

Corporate Fact Sheet Report



“Ingen” is a medical device manufacturing development company that has launched an innovative line of disposable respiratory products that are focused for the emerging growth-oriented home healthcare market. With issued patents, trademarks and secured intellectual property, Ingen’s Oxyview® and Smart Nasal Cannula®, introduced in February 2010, are now the home health care oxygen market’s first oxygen tubing safety devices for patients requiring home oxygen therapy. The company received FDA Registration and Licensing through the Department of Public Health and manufactures these products in Southern California. Ingen has sold more than 120,000 units worldwide in the past few years and is now positioning to increase new distribution channels over the next several months.

INDUSTRY OVERVIEW

Major home healthcare providers and oxygen service providers now debut the Oxyview® product line while they are seeking to capitalize on the booming aging population and the increase in home healthcare services. This market also serves younger, disabled patients who don’t require hospitalization and those recovering from acute medical conditions who only need temporary or intermittent home-based medical care.


Ingen is focused on the worldwide



healthcare market for Oxyview® as it is influenced by a number of demographic trends, including the following:

- Growing and Aging Population: The U.S. Census Bureau predicts that the majority of the U.S. “baby boom” population (28% of the total U.S. population) will begin to turn 65 between 2010 and 2020.
- Consumer expectations for improved healthcare are increasing in both developed and developing countries.
- Technology is giving rise to new clinical therapies, which in turn are addressing more and more medical ailments and aiding in earlier diagnosis, more efficient management and prevention of diseases.

Stock Information



Business:	Medical Equipment
OTC Symbol:	INGT
Recent Price:	\$0.005 (11/05/12)
52-Week Range:	\$0.06 - 0.0001
Average Daily Volume:	222,956
Public Float:	38.1 Million
Shares Outstanding:	89.6 Million
Market Cap:	\$0.45 Million

- Healthcare spending per capita has grown significantly across the world. In the U.S., it has increased from \$144 per capita in 1960 to almost \$4,400 in 1999. Today home healthcare equipment and services in the US have become a very important part of the healthcare industry. Oxyview® has a place in the increasing hospitalization costs that has increased the demand for low-cost alternatives, which in turn, has resulted in the emergence and growth of home healthcare facilities for the elderly, sick and disabled in the country.

MARKETING & KEY CONCEPTS

Ingen’s Oxyview® is a pneumatic metering device that displays and confirms the oxygen flow rate near the patient. Never before has there been a device attached to the oxygen tubing that monitors oxygen flow to the patient. The Oxyview® provides safety, assurance and prevents unnecessary costs associated with malfunctions

The Smart Nasal Cannula
The Only Cannula Verifying Oxygen at the Point of Delivery Where it Matters Most

- Over the Ear Style, Adjustable: Provides secure anchoring for a comfortable and reliable fit.
- Soft, Non-Flared Nasal Tip: Anatomically curved for enhanced comfort and reduced irritation.
- See Place Seamless Design: Eliminates sharp edges and irritation.
- Clear, Lightweight Design: Provides flexibility of movement.
- Oxyview - In-line Flow Meter: Works inside the line to any position on the line. Reduces Patient Anxiety and Service Calls. Increases Patient Satisfaction. Eliminates High-velocity turbulence. FDA Registered Approval.
- Crack Resistant Tubing: Made of a clear, tough, impact resistant material.
- Safe Material Composite: Latex Free. Composites for a patient with very sensitive skin or allergies.
- Disposable or Reusable: Reusable, cannot be attached to the cannula and a disposable unit, or individual as a reusable unit. The reusable unit comes with a removal adapter that fits most tubing.

Call Toll Free 800-250-9622 or visit www.ingen-tech.com

or malpractice issues. The market potential is \$200 Million annually.

HIGHLY COMPETITIVE PRODUCT

Ingen stands at a key reflex point in its history after having developed a unique solution to a growing problem in the \$8 billion per year medical respiratory market. Ingen is positioning to be a global player in the months to come.

RECENT DEVELOPMENTS

09/20/12 -- Ingen Technologies, Inc. is pleased to announce that Richard Campbell (President of RC Product Development & Engineering), David Holland (CEO of SomaLife Consulting LLC) and Michael Cooper (Executive Vice President of SomaLife Consulting LLC) have joined its Board of Directors as referenced in the 8-K filing on September 12, 2012.

"I am extremely gratified that Richard, David and Michael have joined the Ingen Board," said Gary Tilden, Chairman. "They are proven, dependable leaders in their respective fields, care deeply about product sales and corporate growth issues, and will help assist current management in expanding our corporate presence in the various market sectors we specialize in."

Richard Campbell comes from a long successful executive work history with Johnson & Johnson, Abbott Laboratories and government contract manufacturing. A University of California - Los Angeles graduate in engineering, with other business degrees from the University of Chicago and West Coast University, Mr. Campbell will assist with product growth and government sales for Ingen's product line.

David Holland is the Chief Executive Officer for SomaLife Consulting, LLC, and he brings an impressive background of direct sales knowledge to Ingen. With a successful career and experience at the Executive level, David has been involved in all aspects of corporate strategy and the day-to-day operations of the company, and has been the driving force behind many innovative ideas.

Michael Cooper is the Executive Vice President of SomaLife Consulting, LLC with 20 years of experience in sales and business development. Michael holds a B.A. from the University of Florida and an M.B.A. from Florida International University. Michael will assist with sales & marketing strategies for Ingen.

Ingen's first quarter ended August 31, 2012, and the company, will file its quarterly report before October 15th. During the first quarter Ingen exceeded its goals disclosed in the Plan of Reorganization by placing a national distributor for all of its product sales; a leading distributor of home medical and infusion products which promote recovery and active lifestyles for people with disabilities and those who require non-acute medical care. Further, the company delivered 7,760 Oxyview units to this national distributor. Ingen is currently completing the closing of an acquisition of SomaLife in order to expand its product base on a Global basis, which will infuse the company with additional revenues and assets.

"The worldwide market for respiratory devices had an estimated worth of \$4.5 billion in 2010, according to Global Data research, in addition to forecasts predicting a \$2.6 billion increase by 2017. This 7% annual growth rate and the arising, continued significant opportunities for our company will only be enhanced by the addition Richard, David and Michael to our board," continued Chairman Gary Tilden. "We continue working to maintain and increase the level of Board quality at Ingen. Our members and shareholders expect a professionally run organization, which ultimately makes a big difference in how we structure our future growth opportunities. The addition of these new Board members is a further step down that path."

08/28/12 -- Ingen Technologies, Inc. announced today that the company has followed through with its promise to secure a national distributor for the new Oxyview product line. The first purchase order of 7,760 Oxyview units and Smart Nasal Cannulas has been delivered while Ingen prepares for more deliveries. Ingen offers the only

respiratory product of this kind, with a market potential of \$50 Million in annual sales. With the sales support of the largest home healthcare distributor in the world, Ingen gains to benefit with sales through e-commerce and B2B services that are provided through this national distribution program. The product is expected to reach millions of patients suffering with chronic obstructive pulmonary disease who are prescribed home oxygen therapy. The Oxyview products improve home oxygen therapy.

"I am pleased to report that Ingen had a strong first quarter ending on August 31, 2012," stated the Chairman of Ingen, Gary B. Tilden. "We continued to outperform our original projections and met our promise to locate and secure a national distributor; in addition to finding new medical technologies through various acquisition partners, our first pending acquisition being SomaLife LLC. We have also strengthened our Board of Directors with new, experienced individuals that will contribute support and input additional, proactive goals to add stimulus to the growth of the company. At the same time, we continue to stay on track with our plan of reorganization as our responsibility to our shareholders, and for the overall good of the company. Most importantly, we are well positioned to grow as the global economy recovers. These results were made possible by decisions and actions that we undertook six months ago, based on how we believed the world was shifting and to adjust for that change in a manner that would add to our bottom line. But in addition to that, this is a reflection of the mindset, ambitions and values that have guided Ingen during this quarter. As such, our performance in 2012 marks a fitting conclusion to our corporation, and a promising start to our second quarter. Long-term thinking and management that Ingen has practiced this year have positioned this company advantageously for the next five years and beyond."

08/23/12 -- Ingen Technologies, Inc. announced today that the company has received a purchase order for 7,760 Oxyview® units on August 10, 2012.

The National Distributor has agreed to provide all of the E-Commerce and Business-2-Business services for product orders and sales.

The Ingen Oxyview® and Smart Nasal Cannula products will be stocked in our distributor's warehouse inventory and available on their distributor websites on or about the first or second week of September. At that point, Ingen will launch a new website that links the product pages on the Ingen website to their product landing sales pages on our distributor's website. The change from the old direct sales program to the new national distribution program enhances sales and customer service for patients and commercial accounts.

"Our new National Distributor is a leading distributor of home medical and infusion products which promote recovery and active lifestyles for people with disabilities and those who require non-acute medical care. We are working very closely in order to successfully sell our proprietary Oxyview® and Smart Nasal Cannula to the respiratory market. Our new website will launch in September, and all purchases will be routed to our new National Distributor through Electronic Data Interchange (EDI)," stated Gary B. Tilden, Chairman of Ingen.

"Now that we have our national distribution program in place, we will focus our marketing efforts on the government contract we have in place with the Government Services Administration (GSA). This will allow us to distribute future orders from the Department of Defense and VA Hospitals throughout the U.S. and abroad."

08/15/12 -- Ingen Technologies, Inc. announced today that the company has signed a Letter of Intent to acquire SomaLife Consulting LLC.

The Canadian based health products manufacturer is operating in California and will be purchased for \$3 million. This acquisition is estimated to add \$2 million in immediate operating income to Ingen's existing revenue base. The company has completed the due diligence and plans to close escrow in within approximately 90 days.

"David Holland, President of SomaLife, and I expect to begin closing procedures in September," stated Gary Tilden, Chairman of Ingen Technologies. "I have also been very pleased with the progress performed by our Acquisition Team during the time of the negotiations. We had been working diligently for the past 5 months to secure this acquisition, the first of several planned in the future. With additional prospective companies still in line to be reviewed, I am excited about our growth prospects moving forward. These potential, future acquisitions will have to meet our rigid, specific standards in order to even be considered; these would include existing product revenues, intellectual property that is proprietary, and a strong management team. In addition, I would also like to thank my professional staff on their continued efforts on our required report filings, while supporting the Acquisition Team's ongoing efforts. Once finalized, SomaLife Consulting, LLC will become a wholly owned subsidiary of Ingen Technologies."

SomaLife is a private Canadian corporation that manufactures and sells new healthcare products for the sports industry and fitness markets. These products are sold worldwide, and include the Soma Youth Formula, Super-X Antioxidant, SomaVit Multi-Vitamin, Soma Omega-3, Soma IQ-150, SomaSport, and SomaPet (a dietary supplement for animals).

SomaLife entered into a consulting agreement with Luka, Inc. based in San Francisco to assist the roll out of the Virtual Direct Sale Program. Sales of \$125k per month were achieved by the fifth month of the beta test and have continued to increase. North America has the highest market share for the nutraceutical product market. The growth in the North American region is primarily supported by the U.S., as consumers in the U.S. are more conscious about health and food habits. The global nutraceutical market should continue its positive growth. Right now, the United States, Europe and Japan dominate the global market, accounting for a combined market share of more than 85% of the

global market. It is projected that the US market alone will reach \$90 Billion in sales by the end of 2015.

SomaLife has also recently added another target market demographic for its IQ-150 product. This product is geared specifically towards a younger target market, particularly college students. In early 2012, the company entered a joint venture partnership with an LA-based Public Relations and Media firm: Anthony Mora Communication, Inc. The backbone of this project is to develop media material and organize a comprehensive public relations campaign, which includes TV, magazines, newspapers and radio. The Amateur Softball Association of America (ASA), which has 4,000,000 members, is using the company's athletic performance enhancement supplement, SomaSport: www.SomaSport-Softball.com. Marketing initiatives are in place and credit lines are established to facilitate IQ150 sales growth.

08/08/12 -- Ingen Technologies, Inc. announced today that the company Chairman, Gary B. Tilden, has made the following statements regarding an upcoming acquisition.

"I am very pleased to announce that Ingen will be making several acquisitions over the next 12 months as a part of its Plan of Reorganization. The first acquisition should be announced in the next few days regarding a company with a proprietary, patented line of products for the healthcare industry. This is a monumental step forward for Ingen in building a solid foundation in which to grow upon. We believe that we have a strong medical product base that will continue to create longevity for our overall increasing revenue base. In addition, the potential market for our respiratory product line is approximately \$200 million annually; and the new addition of this upcoming acquisition will open up new markets for Ingen in the healthcare and health & fitness industry."

08/07/12 -- Ingen Technologies, Inc. announced today that the company has agreed to deliver approximately 8,000 Oxyview units in value of \$160,000.

The first purchase order will include the reusable Oxyview oxygen flow meter model 203A and 206A; and the disposable adult-size Smart Nasal Cannula. The company currently has 80,000 units in stock and will meet demands from the National Distributor over the next few months. Ingen has the manufacturing processes and tooling capabilities to produce 100,000 Oxyview units on a monthly basis, in value of \$2M.

“In the US alone, there are over 30 million patients diagnosed with Chronic Obstructive Pulmonary Disease, and the majority of these patients require home oxygen therapy. The disposable Smart Nasal Cannula and the Oxyview will be introduced to the majority of these patients through the national distributor and large medical service providers,” stated Gary Tilden, Chairman.

07/27/12 -- Ingen Technologies, Inc. announced today that the company has finalized its sales program with one of the largest medical suppliers in North America. All sales, e-commerce and business-to-business will be provided through this major supplier. The Ingen website is now being rebuilt to reflect the new medical supplier and national sales program. Ingen expects to have this transition complete in the

next several weeks, at which time an announcement will be made.

Ingen is licensed in the State of California with the Department of Public Health to manufacture its Oxyview and Smart Nasal Cannula product line. These patented & proprietary medical products are now globally distributed to the respiratory industry and registered with the U.S. FDA (Food & Drug Administration). Please refer to the most recent Annual Report ending May 31, 2012 for current information about the medical technologies owned and manufactured by Ingen. This report is found at the following link: <http://www.otcmarkets.com/financialReportViewer?symbol=IGNT&id=86111>

Further, Ingen has been negotiating for several months with another large medical supplier who is a major player in selling medical products to various government medical facilities. “We are now directing our focus on closing this agreement in order to deliver products to VA Hospitals and to the Department of Defense. We received a GSA Department of Veterans Affairs Federal Supply Contract Award in 2011 and will distribute our medical products to VA Hospitals and to the Department of Defense in 2013,” stated the Chairman, Gary B. Tilden.

07/10/12 -- Ingen Technologies, Inc. announced today that the company is moving forward with a leading national medical supplier for the home healthcare and hospital markets. As previously mentioned in an earlier press release an announcement will be made at the proper time in the near future.

In order to keep our financial information current with the OTC Pink Sheets, we plan on issuing our unaudited annual report ending May 31st, 2012 later this week. This will give investors a true picture of our current financial position. “We are working hard to bring our shareholders straightforward and up to date information so they are able to make informed and intelligent decisions,” stated Gary Tilden, Chairman and COO of Ingen Technologies, Inc.

Contact:

Ingen Technologies, Inc
3410 La Sierra Avenue.
Suite F507
Riverside, CA 92503
Phone: 951-688-7840
Fax: 951-688-8802
Email: info@ingen-tech.com
Web: www.ingen-tech.com

Disclaimer:

This is a paid advertisement. OTC Special Situations Report (OTCSSR) is a publication of National Financial Communications Corp. (NFC). NFC was paid twelve million restricted shares for the composition, design, and endorsement by the featured company in addition to editorial fees for the cost of dissemination. The companies featured in OTCSSR do not have to meet any specific financial criteria and are typically developmental stage companies that pose a much greater risk to investors and an investment of this type could result in a TOTAL LOSS over a period of time. Release of Liability: Through use of this advertisement (marketing piece) viewing or referencing, you agree to hold NFC Corp, its operators and associates harmless of any actions taken by you and to completely release NFC from any and all liability due to any and all losses (monetary or otherwise), or injury (monetary or otherwise) that you may incur from actions taken through information obtained in this piece. The information contained herein contains forward-looking statements and information within the meaning of Section 27A of the Securities Act of 1993 and Section 21E of the Securities Exchange Act of 1934, including statements regarding expected continual growth of the featured company. In accordance with safe harbor provisions of the Private Securities Litigation Reform Act of 1995, the statements contained herein that look forward in time, which include other than historical information, involve risks and uncertainties that may affect actual results of operations. Factors that could cause actual results to differ include the size and growth of the market for the company's products or services, the company's ability to fund its capital requirements in the near term and in the long term, pricing pressures, etc. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives goals, assumptions or future events or performance may be forward-looking statements. Forward-looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward-looking statements may be identified through the use of words such as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should or might occur. This is not an offer to buy or sell securities. Information or opinions in this report are presented solely for informative purposes, and are not intended nor should they be construed as investment advice. The information provided in this report is not intended for distribution to, or use by, any person or entity in any jurisdiction or country where such distribution or use would be contrary to law or regulation or which would subject us to any registration requirement within such jurisdiction or country. We encourage our readers to invest carefully and read the investor information available at the web sites of the U.S. Securities and Exchange Commission (SEC) at www.sec.gov and the National Association of Securities Dealers (NASD) at www.nasd.com. The NASD has published information on how to invest carefully at its web site. Readers can review all public filings by companies at the SEC's EDGAR page. This report does not purport to be a complete study of the featured Company. Information used and statements of fact have been obtained from the featured Company and other sources, but NOT VERIFIED OR GUARANTEED by OTCSSR as to completeness or accuracy. Such information is subject to change without notice. It should be understood that there is no guarantee past performance will be indicative of future results. Opinions stated herein may be solely Geoffrey Eiten's, and not necessarily those of the featured Company. Officers, directors, and employees of NFC and anyone mentioned in this report, and members of their families may hold a position and may, from time to time, trade in these securities for their own accounts including when this report is distributed. Specific information in this regard will be furnished upon request. Trademarks are the property of their respective owners. ©2012 OTC Special Situations Report. All rights reserved. For any additional information call 781-444-6100 or see www.otcfn.com